Galimedix, Inc. | WebDisclosure

Basculer en Français

10964	Companies
239970	Keywords
168738	Articles
129110	Press releases

Home
Companies
Galimedix, Inc.

PRESS RELEASE

published on 05/06/2025 at 14:00, 1 year 4 months ago

Galimedix Therapeutics completes single ascending dose part of Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator
Galimedix Therapeutics completes single ascending dose of Phase 1 study with oral small molecule GAL-101 targeting amyloid beta aggregation modulator, supporting oral administration route. Next study arms and indications revealed

Galimedix Therapeutics GAL-101 Oral Administration Phase 1 Study Amyloid Beta
BRIEF

published on 04/01/2025 at 09:05, 1 year 5 months ago

Galimedix Reports Promising Data for Alzheimer's Treatment

Alzheimer's Disease GAL-201 Galimedix Therapeutics Neuroinflammation Amyloid-β Aggregation
BRIEF

published on 04/01/2025 at 09:05, 1 year 5 months ago

Galimedix publie des données prometteuses pour le traitement de la maladie d'Alzheimer

GAL-201 Maladie D'Alzheimer Galimedix Therapeutics Neuroinflammation Agrégation De L'amyloïde-β
PRESS RELEASE

published on 04/01/2025 at 09:00, 1 year 5 months ago

Galimedix Therapeutics presents further scientific data showing disease-modifying potential of oral GAL-201 in Alzheimer’s disease as well as beneficial effects on synaptic function and neuroimmunomod
Galimedix Therapeutics presents new preclinical data on GAL-201 at AD/PD 2025, showing promise in Alzheimer’s disease treatment by targeting misfolded Aβ monomers and reducing Aβ plaques with anti-inflammatory effects

Alzheimer's Disease Preclinical Data GAL-201 Galimedix Therapeutics Neuroinflammation
BRIEF

published on 03/24/2025 at 15:12, 1 year 5 months ago

Galimedix Therapeutics présente un traitement préclinique prometteur contre la maladie d'Alzheimer

Galimedix Therapeutics Neuroprotection Données Précliniques Traitement De La Maladie D'Alzheimer Bêta-amyloïde
BRIEF

published on 03/24/2025 at 15:12, 1 year 5 months ago

Galimedix Therapeutics to Present Promising Preclinical Alzheimer’s Treatment

Preclinical Data Galimedix Therapeutics Neuroprotection Alzheimer's Treatment Amyloid-beta
PRESS RELEASE

published on 03/24/2025 at 15:07, 1 year 5 months ago

Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator in development for oral Alzheimer’s disease treatment at AD/PD™ 2025 Conference
Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator for oral Alzheimer's disease treatment at AD/PD(TM) 2025 Conference

Alzheimer's Disease Galimedix Therapeutics Pre-clinical Data AD/PD 2025 Conference Aβ Aggregation Modulator
BRIEF

published on 12/23/2024 at 17:35, 1 year 8 months ago

Galimedix débute un essai de phase 2 avec les gouttes ophtalmiques GAL-101 pour la DMLA sèche

Étude De Phase 2 Neuroprotection GAL-101 DMLA Sèche Atrophie Géographique
BRIEF

published on 12/23/2024 at 17:35, 1 year 8 months ago

Galimedix Begins Phase 2 Trial with GAL-101 Eye Drops for Dry AMD

Phase 2 Study Neuroprotection GAL-101 Dry AMD Geographic Atrophy
PRESS RELEASE

published on 12/23/2024 at 17:30, 1 year 8 months ago

Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD
Galimedix Therapeutics initiates Phase 2 study with GAL-101 eye drops for dry AMD, aiming to slow geographic atrophy growth. Trial led by world-leading retina experts and funded by Théa Open Innovation

Galimedix Therapeutics Phase 2 Study GAL-101 Dry AMD Geographic Atrophy

Accesswire

Published on 09/11/2026 at 04:00, 3 hours 30 minutes ago

Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 9 hours 5 minutes ago

Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 17:46, 13 hours 44 minutes ago

Groete Access Road Nears Completion
Published on 09/10/2026 at 15:20, 16 hours 10 minutes ago

MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 16 hours 30 minutes ago

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)

View all ACCESSWIRE

EQS Group

Published on 09/11/2026 at 00:05, 7 hours 25 minutes ago

Club Offers for Travel Enthusiasts in Germany
Published on 09/11/2026 at 00:01, 7 hours 29 minutes ago

Club Offers for Travel Enthusiasts in Germany
Published on 09/10/2026 at 22:39, 8 hours 51 minutes ago

EQS-Adhoc: Notice by Rumble Deutschland AG regarding an upcoming squeeze-out under German Stock Corporation Law
Published on 09/10/2026 at 22:10, 9 hours 20 minutes ago

flatexDEGIRO with changes to the Supervisory Board
Published on 09/10/2026 at 22:07, 9 hours 23 minutes ago

EQS-Adhoc: flatexDEGIRO SE: Changes to the Supervisory Board

Les Echos

Published on 09/11/2026 at 07:00, 30 minutes ago

Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 30 minutes ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 30 minutes ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 30 minutes ago

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 12 hours ago

Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE